|
Market Closed -
Other stock markets
|
After market 04:00:00 pm | |||
| 90 EUR | +0.94% |
|
90.14 | +0.15% |
| 01:48pm | Sanofi Partners with Microsoft-Backed OpenAI, Formation Bio to Develop Drugs with AI | MT |
| 09:02am | Sanofi: cooperation with Formation Bio and OpenAI | CF |
PARIS, Jan 23 (Reuters) - French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday.
As part of this deal, Inhibrx Inc shareholders will get $30 per share in cash, one contingent value right (CVR) equal to $5 and 0.25 shares in New Inhibrx, a new publicly traded company. (Reporting by Sudip Kar-Gupta; editing by Christian Schmollinger)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 11,956 PTS | +2.29% | +9.48% | - | ||
| 90 EUR | +0.94% | -1.84% | 121B | ||
| 34.24 USD | -0.64% | +0.29% | 1.81B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +0.27% | 121B | |
| +37.78% | 705B | |
| +32.82% | 583B | |
| -3.51% | 364B | |
| +19.94% | 332B | |
| +5.14% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +9.32% | 169B |
SANOFI 
